Browse our 650+ Publications
Latest Publications
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial
Shenderov E, et al.
April 2023
Authors and Affiliates
Eugene Shenderov 1,2, Angelo M De Marzo 3,4,5, Tamara L Lotan 3,4,5, Hao Wang 6, Sin Chan 3, Su Jin Lim 6, Hongkai Ji 7, Mohamad E Allaf 5, Carolyn Chapman 3, Paul A Moore 8, Francine Chen 8, Kristina Sorg 9, Andrew M White 9, Sarah E Church 9, Briana Hudson 9, Paul A Fields 10, Shaohui Hu 11, Samuel R Denmeade 3, Kenneth J Pienta 3, Christian P Pavlovich 5, Ashley E Ross 12, Charles G Drake 13, Drew M Pardoll 3,14, Emmanuel S Antonarakis 3,14,15;
1 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu.
2 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA. Eugene.Shenderov@jhmi.edu.
3 Department of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
4 Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
5 Department of Urology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
6 Department of Oncology Biostatistics and Bioinformatics, Johns Hopkins School of Medicine, Baltimore, MD, USA.
7 Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
8 MacroGenics, Inc., Rockville, MD, USA.
9 NanoString Technologies Inc., Seattle, WA, USA.
10 Adaptive Biotechnologies, Seattle, WA, USA.
11 CDI Labs, Baltimore, MD, USA.
12 Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
13 Immuno-Oncology, Janssen, Horsham, PA, USA.
14 The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins School of Medicine, Baltimore, MD, USA.
15 University of Minnesota Masonic Cancer Center, Minneapolis, MN, USA.
T cell immunity is key to the pandemic endgame: How to measure and monitor it
Schwarz M, et al,
April 2023
Authors and Affiliates
Megan Schwarz 1,2, Slim Mzoughi 1,2, Daniel Lozano-Ojalvo 3, Anthony T Tan 4, Antonio Bertoletti 4, Ernesto Guccione 1,2,5;
1 Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, NY, USA.
2 Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
3 Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, NY, USA.
4 Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore.
5 Bioinformatics for Next Generation Sequencing (BiNGS) Shared Resource Facility, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Multiparameter flow cytometry and ClonoSEQ correlation to evaluate precursor B-lymphoblastic leukemia measurable residual disease
Momen N, et al.
Journal of Hematopathology
April 2023
Authors and Affiliates
Nouran Momen1,2 Joseph Tario1 Kai Fu1 You‑Wen Qian1
1 Department of Pathology, Roswell Park Cancer Institute, Basic Science Building, Room 529, Elm St & Carlton St, Buffalo, NY 14203, USA
2 Clinical & Chemical Pathology Department, Cairo University, Cairo, Egypt
Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.
Younes A, et al.
Blood Advances
April 2023
Authors and Affiliates
Anas Younes,1 John M. Burke,2 Bruce D. Cheson,3 Catherine S. Diefenbach,4 Silvia Ferrari,5 Uwe H. Hahn,6 Eliza A. Hawkes,7 Cyrus Khan,8 Izidore S. Lossos,9 Gerardo Musuraca,10 Monica Tani,11 Umberto Vitolo,12 Sam Yuen,13 Aparna Raval,14 Mahesh Shivhare,15 Tina G. Nielsen,16 Gila Sellam,16 Jeff P. Sharman,17
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, NY, USA; 2Rocky Mountain Cancer Centers & US Oncology, Aurora, CO, USA; 3Georgetown University Hospital, Washington, DC, USA*; 4
Clinical Lymphoma program, Perlmutter Cancer Center at NYU Langone Health, New York City, NY, USA; 5Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; 6Department of Haematology, Royal Adelaide and Queen Elizabeth Hospital, Adelaide, SA, Australia; 7Department of Haematology,Olivia Newton-John Cancer Research Institute, Austin Health, Melbourne, VIC, Australia; 8Division of Hematology and Cellular Therapy, Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA; 9Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, Miami, FL, USA; 10Hematology unit, IRCCS, Istituto Romagnolo per lo Studio dei Tumori (IRST), Meldola, Italy; 11Division of Hematology, Santa Maria delle Croci Hospital, Ravenna, Italy; 12Multidisciplinary Oncology Outpatient Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy; 13Department of Haematology, Calvary Mater, Newcastle, NSW, Australia; 14Oncology Biomarker Development,Genentech, Inc, South San Francisco, CA, USA**; 15Data and statistical Science, Roche Products Ltd, Welwyn Garden City, United Kingdom; 16Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland; 17US Oncology Research, Willamette Valley Cancer Institute / US Oncology Research, Eugene, OR, USA
Interpretable artificial intelligence model for accurate identification of medical conditions using immune repertoire
Zhao Y, et al.
April 2023
Authors and Affiliates
Yu Zhao 1, Bing He 1, Zhimeng Xu 1, Yidan Zhang 1,2, Xuan Zhao 1, Zhi-An Huang 1,3, Fan Yang 1, Liang Wang 1, Lei Duan 2, Jiangning Song 1,4, Jianhua Yao 1;
1 AI Lab, Tencent, Shenzhen, China.
2 School of Computer Science, Sichuan University, Chengdu, China.
3 Center for Computer Science and Information Technology, City University of Hong Kong Dongguan Research Institute, Dongguan, China.
4 Monash Biomedicine Discovery Institute and Monash Data Futures Institute, Monash University, Melbourne, VIC 3800, Australia.
Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancer
Yoshida-Court K, et al.
April 2023
Authors and Affiliates
Kyoko Yoshida-Court 1, Tatiana V Karpinets 2, Aparna Mitra 1, Travis N Solley 1, Stephanie Dorta-Estremera 3, Travis T Sims 4, Andrea Y Delgado Medrano 1, Molly B El Alam 1, Mustapha Ahmed-Kaddar 1, Erica J Lynn 1, K Jagannadha Sastry 5, Jianhua Zhang 2, Andrew Futreal 2, Alpa Nick 6,7, Karen Lu 4, Lauren E Colbert 1, Ann H Klopp 1;
1 Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
2 Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
3 Comprehensive Cancer Center, Cancer Biology, Department of Microbiology and Zoology, University of Puerto Rico, Medical Sciences Campus, San Juan, Puerto Rico.
4 Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
5 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
6 Saint Thomas Health/Ascension, Nashville, TN, United States of America.
7 Tennessee Oncology, Nashville, Tennessee, United States of America.
Clonally expanded HIV-1 proviruses with 5′-leader defects can give rise to nonsuppressible residual viremia
White JA, et al.
April 2023
Authors and Affiliates
Jennifer A White 1, Fengting Wu 1, Saif Yasin 2, Milica Moskovljevic 1, Joseph Varriale 1, Filippo Dragoni 1, Angelica Camilo-Contreras 1, Jiayi Duan 1, Mei Y Zheng 2, Ndeh F Tadzong 2, Heer B Patel 2, Jeanelle Mae C Quiambao 2, Kyle Rhodehouse 1, Hao Zhang 3, Jun Lai 1, Subul A Beg 1, Michael Delannoy 4, Christin Kilcrease 1, Christopher J Hoffmann 1, Sébastien Poulin 5, Frédéric Chano 5, Cécile Tremblay 6,7, Jerald Cherian 1, Patricia Barditch-Crovo 1, Natasha Chida 1, Richard D Moore 1, Michael F Summers 2,8, Robert F Siliciano 1,8, Janet D Siliciano 1, Francesco R Simonetti 1;
1 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
2 Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, Baltimore, Maryland, USA.
3 Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
4 Institute for Basic Biomedical Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
5 Clinique L'Agora, Montreal, Canada.
6 Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, Canada.
7 Département de Microbiologie, Immunologie et Infectiologie, Université de Montréal, Montreal, Canada.
8 Howard Hughes Medical Institute, Baltimore, Maryland, USA.
Thymic atrophy creates holes in Treg-mediated immuno-regulation via impairment of an antigen-specific clone
Thomas R, et al.
April 2023
Authors and Affiliates
Rachel Thomas 1, Jiyoung Oh 2, Weikan Wang 1, Dong-Ming Su 3;
1 Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, USA.
2 Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
3 Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX, USA.
Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
Sinha M, et al.
April 2023
Authors and Affiliates
Meenal Sinha 1, Courtney Betts 2, Li Zhang 1,3, Madeline J Griffith 1, Isabelle Solman 4, Brandon Chen 1, Eric Liu 1, Whitney Tamaki 1, Jacob Stultz 1, Jaqueline Marquez 1, Shamilene Sivagnanam 2, Alexander Cheung 1, Denise Pener 5, Anne Fahlman 5, Erin Taber 5, Kimberly Lerner 5, Matthew Crocker 5, Kendra Todd 5, Brindha Rajagopalan 5, Clarisha Ware 1, Mark Bridge 1, Johnson Vo 5, Hannah Dragomanovich 1, Julie Sudduth-Klinger 1, Gina Vaccaro 6, Charles D Lopez 2,5, Margaret Tempero 1, Lisa M Coussens # 2, Lawrence Fong # 7,8;
1 Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA.
2 Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.
3 Department of Biostatistics, University of California, San Francisco, California, USA.
4 AbbVie, Irvine, California, USA.
5 Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
6 Medical Oncology, Providence Portland Medical Center, Portland, Oregon, USA.
7 Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA lawrence.fong@ucsf.edu.
8 Parker Institute for Cancer Immunotherapy, San Francisco, California, USA.
#Contributed equally.